The novel dopamine D2/D3 receptor agonist radioligand [18F]MCL-524 is sensitive to dopamine levels

被引：0
|
作者：
Finnema, Sjoerd [1 ]
Stepanov, Vladimir [1 ]
Nakao, Ryuji [1 ]
Amini, Nahid [1 ]
Sromek, Anna [2 ]
Neumeyer, John [2 ]
Seeman, Philip [3 ]
Farde, Lars [1 ]
Halldin, Christer [1 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[2] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA USA
[3] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [1] Radiolabeling and monkey PET evaluation of the dopamine D2 and D3 receptor agonist radioligand [18F]MCL-524
    Stepanov, Vladimir
    Finnema, Sjoerd J.
    Nakao, Ryuji
    Sromek, Anna W.
    Zhang Tang-Zhi
    Neumeyer, John L.
    Susan, George R.
    Seeman, Philip
    Farde, Lars
    Halldin, Christer
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S9 - S9
  • [2] The First PET Evaluation of the Fluorine-18 Labeled Dopamine D2/D3 Receptors Agonist, [18F]MCL-524
    Finnema, S. J.
    Stepanov, V.
    Nakao, R.
    Sromek, A. W.
    Zhang, T. Z.
    Neumeyer, J. L.
    George, S. R.
    Seeman, P.
    Farde, L.
    Halldin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S188 - S188
  • [3] [18F] MCL-524, an 18 F-labeled dopamine D2/D3 receptors agonist radioligand with higher binding signal than [11C] MNPA
    Finnema, Sjoerd
    Stepanov, Vladimir
    Nakao, Ryuji
    Sromek, Anna
    Neumeyer, John
    Seeman, Philip
    Farde, Lars
    Halldin, Christer
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [4] 18F-MCL-524, an 18F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study
    Finnema, Sjoerd J.
    Stepanov, Vladimir
    Nakao, Ryuji
    Sromek, Anna W.
    Zhang, Tangzhi
    Neumeyer, John L.
    George, Susan R.
    Seeman, Philip
    Stabin, Michael G.
    Jonsson, Cathrine
    Farde, Lars
    Halldin, Christer
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (07) : 1164 - 1170
  • [5] Quantification and Whole-Body Distribution of a Novel Dopamine D2/D3 Receptor Agonist, [18F]MCL-524, in Monkeys: A Prediction for Application in Human Subjects
    Finnema, S. J.
    Stepanov, V.
    Nakao, R.
    Amini, N.
    Sromek, A. W.
    Neumeyer, J. L.
    Seeman, P.
    Stabin, M. G.
    Farde, L.
    Halldin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S181 - S182
  • [6] The Non-Anhydrous, Minimally Basic Synthesis of the Dopamine D2 Agonist [18F]MCL-524
    Inkster, James A. H.
    Sromek, Anna W.
    Akurathi, Vamsidhar
    Neumeyer, John L.
    Packard, Alan B.
    CHEMISTRY-SWITZERLAND, 2021, 3 (03): : 1047 - 1056
  • [7] Autoradiography and microPET rodent evaluation of the [18F]MCL-524-an 18F-labelled dopamine D2/D3 receptor agonist
    Stepanov, V.
    Haeggkvist, J.
    Svedberg, M.
    Krasikova, R.
    Finnema, S. J.
    Sromek, A. W.
    Neumeyer, J. L.
    Halldin, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S120 - S121
  • [8] Gender Differences in Dopamine D3 Receptor Availability as Determined by [18F]Fluortriopride, a Dopamine D3 Receptor Selective Radiotracer
    Dubroff, Jacob
    Doot, Robert
    Ward, Chris
    Cai, Jenny
    Labban, Kyle
    Lee, Hsiaoju
    Hsieh, Chia-Ju
    Xu, Kuiying
    Schubert, Erin
    Li, Shihong
    Hou, Catherine
    Sheffer, Regan
    Schmitz, Alex
    Mach, Robert
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S450 - S450
  • [9] 18F-5-OH-FHXPAT:: A new dopamine D2/D3 receptor agonist radiotracer.
    Chattopadhyay, S
    Xue, B
    Shi, B
    Mukherjee, J
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 187P - 187P
  • [10] Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets:: Mediation by D2, not D3, dopamine receptors
    Hill, Michael P.
    Ravenscroft, Paula
    McGuire, Steven G.
    Brotchie, Jonathan M.
    Crossman, Alan R.
    Rochat, Catherine
    Millan, Mark J.
    MOVEMENT DISORDERS, 2006, 21 (12) : 2090 - 2095
12345